Session 8: Debate: Triplet Chemotherapy (FOLFOXIRI) + Bevacizumab vs Doublet Chemotherapy (FOLFOX/FOLFIRI) + Panitumumab for Left-sided all RAS Wild-Type Metastatic Colorectal Cancer (mCRC) - Doublet Chemo + Panitumumab

Presenter(s)

• 

  Smitha Krishnamurthi, MD

  Department of Hematology and Oncology at Cleveland Clinic